Milestone raises $80M to fund pivotal trial of at-home tachycardia therapy

Milestone Pharmaceuticals Inc. (Montreal, Quebec) raised $80 million in a series D on Oct. 25 to support a Phase III trial of its self-administered acute paroxysmal supraventricular

Read the full 277 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE